Research Topics
Species | Daniel J LovellSummaryAffiliation: Cincinnati Children's Hospital Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Summary of worldwide pediatric malignancies reported after exposure to etanerceptPeter McCroskery
Amgen Inc, Thousand Oaks, CA, Seattle WA, and South San Francisco, CA, USA
Pediatr Rheumatol Online J 8:18. 2010..We examined the worldwide experience of etanercept use in pediatric patients and the occurrence of malignancies as reported from clinical trials, registry studies, post-marketing surveillance, and published scientific literature...
A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritisDaniel J Lovell
Cincinnati Children s Hospital Medical Center, William S Rowe Division of Rheumatology ML4010, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Arthritis Rheum 54:2235-42. 2006....- Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisDaniel J Lovell
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Arthritis Rheum 54:1987-94. 2006..The goal of our study was to provide data on safety and efficacy after 4 years of etanercept treatment in patients with JRA... - Pediatric clinical researchDaniel J Lovell
Cincinnati Children s Hospital, Cincinnati, Ohio 45229, USA
Curr Opin Rheumatol 17:265-70. 2005..This review will focus on childhood-onset systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis, with special interest on strategies to improve the health-related quality of life in these conditions... - Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory diseaseDaniel J Lovell
Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
Arthritis Rheum 52:1283-6. 2005..These observations suggest that IL-1 plays a critical role in the pathogenesis of this inflammatory disease, and that blockade with anakinra should be further studied as a treatment for patients with NOMID and related disorders... 
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritisDaniel J Lovell
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Arthritis Rheum 58:1496-504. 2008..To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)...- Adalimumab with or without methotrexate in juvenile rheumatoid arthritisDaniel J Lovell
Cincinnati Children s Hospital Medical Center, Division of Rheumatology, Location E, Rm 2 129, MLC 4010, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
N Engl J Med 359:810-20. 2008..We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis... - Biologic agents for the treatment of juvenile rheumatoid arthritis: current statusRuy Carrasco
Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Paediatr Drugs 6:137-46. 2004..Randomized trials are ongoing to better define both the efficacy and safety of these novel treatments for children with JRA and other rheumatic diseases... - Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trialDaniel J Lovell
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
Arthritis Rheum 48:218-26. 2003..All patients had been participants in an initial randomized efficacy and safety trial of etanercept... - Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritisDaniel J Lovell
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Arthritis Care Res (Hoboken) 63:10-6. 2011..The objective of this effort was to establish a set of QMs for the assessment of the process of care in juvenile idiopathic arthritis (JIA)... - Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trialRuy Carrasco
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Arthritis Rheum 58:3932-40. 2008.... - Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritisEdward H Giannini
Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Arthritis Rheum 62:3259-64. 2010..To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA)... - Minimal clinically important differences of the childhood health assessment questionnaireHermine I Brunner
Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
J Rheumatol 32:150-61. 2005..125. We estimated minimal clinically important differences (MCID) of the CHAQ for worsening and improvement that were actually experienced by children with JRA using patient, parent, and clinical perspectives... - Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaireHermine I Brunner
Division of Rheumatology E 4010, Cincinnati Children s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
J Clin Rheumatol 11:194-204. 2005.... - Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritisAndrea C Barron
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229-3039, USA
Arthritis Rheum 51:899-908. 2004..Relatively large WTP estimates support a possible important negative impact of the disease on families of children with JIA... - Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgiaSusmita Kashikar-Zuck
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio Electronic address
J Pain 14:492-501. 2013..Clinicians treating adolescents with JFM should focus on teaching a variety of adaptive coping strategies to help patients simultaneously regain functioning and improve mood... - Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trialSusmita Kashikar-Zuck
Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Arthritis Rheum 64:297-305. 2012.... - Preliminary definition of disease flare in juvenile rheumatoid arthritisHermine I Brunner
William S Rowe Division of Rheumatology, Cincinnati Children s Hospital Medical Center, OH 45229, USA
J Rheumatol 29:1058-64. 2002..To develop preliminary criteria for defining disease flare in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)... - Disease control and health-related quality of life in juvenile idiopathic arthritisMichael Seid
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
Arthritis Rheum 61:393-9. 2009.... - Update on treatment of arthritis in children: new treatments, new goalsDaniel J Lovell
Children's Hospital Medical Center, Location E, Room 2-129, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA
Bull NYU Hosp Jt Dis 64:72-6. 2006..In systemic JIA approximately 50% respond to anti-TNF agents, but in many the response is not sustained. Openlabel studies have shown promising results for biologic therapies that block interleukins 1 and 6 in systemic JIA... - Actigraphy-based physical activity monitoring in adolescents with juvenile primary fibromyalgia syndromeSusmita Kashikar-Zuck
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
J Pain 11:885-93. 2010..Results indicate that actigraphy provides a unique source of objective information that can advance our understanding of physical disability in JPFS and the factors associated with physical impairment... - Relationship between school absenteeism and depressive symptoms among adolescents with juvenile fibromyalgiaSusmita Kashikar-Zuck
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
J Pediatr Psychol 35:996-1004. 2010..To describe school absences in adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS) and examine the relationship between school absenteeism, pain, psychiatric symptoms, and maternal pain history... - Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathyNdate Fall
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
Arthritis Rheum 52:3175-80. 2005..To investigate the relationship between the vasculopathy of juvenile dermatomyositis (juvenile DM) and the balance between the angiostatic ELR- and angiogenic ELR+ CXC chemokines in the muscle of patients with the disease... - Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reportingHermine I Brunner
Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
Arthritis Rheum 51:763-73. 2004..To evaluate whether HRQOL scores vary as a function of disability status beyond chance. To assess the quality of the parent proxy report for HRQOL as compared with disability, pain, and well-being... - Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcomePatricia E Ladd
Department of Pediatric Radiology, Cincinnati Children s Hospital Medical Center, OH 45229, USA
AJR Am J Roentgenol 197:W153-8. 2011..The purpose of our study is to determine whether initial MRI findings in the pelvis and thighs in children with JDMS can predict clinical disease course... - Parents' Information Needs in Tumor Necrosis Factor-α Inhibitor Treatment DecisionsEllen A Lipstein
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
J Pediatr Gastroenterol Nutr 56:244-50. 2013..The aim of the study was to describe parents' experiences and the information used when making decisions about tumor necrosis factor-α inhibitor (TNFαi) treatment... - Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in childrenMarissa J Perman
Division of Dermatology, College of Medicine, University of Cincinnati and Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Pediatr Dermatol 29:454-9. 2012..We hope that clinicians caring for patients receiving anti-TNF-α agents will consider psoriasis from the onset of cutaneous symptoms and institute appropriate therapy or referral... - Prevention of osteoporosis: a randomized clinical trial to increase calcium intake in children with juvenile rheumatoid arthritisLori J Stark
Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Division of Psychology, Sec 4, Cincinnati, Ohio 45229, USA
J Pediatr Psychol 30:377-86. 2005..To test the efficacy of a behavioral intervention (BI) compared to an enhanced standard of care (ESC) dietary counseling on increasing dietary calcium (Ca) intake in children with juvenile rheumatoid arthritis (JRA)... - A randomized clinical trial of dietary calcium to improve bone accretion in children with juvenile rheumatoid arthritisLori J Stark
Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center University of Cincinnati College of Medicine, OH 45229, USA
J Pediatr 148:501-7. 2006..To examine a behavioral intervention (BI) to increase calcium intake in children with juvenile rheumatoid arthritis (JRA) on calcium intake and bone mass 6 and 12 months after treatment... - Advanced therapy for juvenile arthritisKevin J Murray
Paediatric Rheumatology Unit, Great Ormond St Hospital for Children, London WC1N 3JH, UK
Best Pract Res Clin Rheumatol 16:361-78. 2002.... - De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseasesIvona Aksentijevich
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
Arthritis Rheum 46:3340-8. 2002.... - Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosisSuzanne L Bowyer
Pediatric Rheumatology Divisions, Indiana University, Indianapolis, Indiana, USA
J Rheumatol 30:394-400. 2003..Radiographically evident joint space damage was seen within a year of onset in poly patients, and by 5 years 2/3 of poly and systemic patients had damage... - A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritisNicolino Ruperto
IRCCS, Istituto G Gaslini, Genoa, Italy
Arthritis Rheum 56:3096-106. 2007..To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA)... - Immunosuppressants, infection, and inflammationDaniel J Lovell
Division Immunologic Infectious Disease, Children's Hospital of Philadelphia, PA 19104, USA
Clin Immunol 113:137-9. 2004 - Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialNicolino Ruperto
IRCCS G Gaslini, PRINTO, Genoa, Italy
Lancet 372:383-91. 2008..We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments... - Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extensionAndreas Reiff
Children's Hospital Los Angeles, Los Angeles, CA, USA
J Rheumatol 33:985-95. 2006..5 or 25 mg was well tolerated, providing sustained clinical effectiveness comparable to naproxen 15 mg/kg. *On September 30, 2004, Merck & Co., Inc. announced the voluntary worldwide withdrawal of rofecoxib from the market... - Performing trials in children with rheumatic diseases: comment on the editorial by LehmanNicolino Ruperto
Arthritis Rheum 58:1201-2; author reply 1203. 2008 - The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core setNicolino Ruperto
Pediatric Rheumatology International Trials Organization PRINTO, IRCCS G Gaslini, Universita di Genova, Pediatria II Reumatologia, Largo Gaslini, Genoa, Italy
Arthritis Rheum 52:2854-64. 2005..To validate and promulgate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile systemic lupus erythematosus (SLE)... - The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective vaNicolino Ruperto
IRCCS G Gaslini, Genoa, Italy
Arthritis Rheum 59:4-13. 2008..To validate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile dermatomyositis (DM)... - Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositisNicolino Ruperto
IRCCS G Gasalini, Pediatria II, Genova, Italy
Rheumatology (Oxford) 42:1452-9. 2003..To identify preliminary core sets of outcome variables for disease activity and damage assessment in juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM)...
Research Grants
- CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGYDaniel Lovell; Fiscal Year: 2004..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..